Abstract
More than 80% of patients with PMF harbor DNA variants/mutations other than JAK2/CALR/MPL. Some of these variants/mutations adversely affect overall or leukemia-free survival independent of conventional risk stratification.
Cite
CITATION STYLE
APA
Tefferi, A., Lasho, T. L., Finke, C. M., Elala, Y., Hanson, C. A., Ketterling, R. P., … Pardanani, A. (2016). Targeted deep sequencing in primary myelofibrosis. Blood Advances, 1(2), 105–111. https://doi.org/10.1182/bloodadvances.2016000208
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free